Fixed-dose oral direct thrombin inhibitor ximelagatran as an alternative for dose-adjusted warfarin in patients with non-valvular atrial fibrillation

被引：0
|
作者：
Olsson, BB
Petersen, P
机构：
[1] Univ Lund Hosp, Dept Cardiol, S-22185 Lund, Sweden
[2] Univ Copenhagen Hosp, Med Ctr, Div Stroke, Hvidovre, Denmark
来源：
EUROPEAN HEART JOURNAL | 2001年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：330 / 330
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of a new oral direct thrombin inhibitor Dabigatran in atrial fibrillation - a dose finding trial with comparison to Warfarin
    Wallentin, L. C.
    Ezekowitz, M.
    Simmers, T. A.
    Pedersen, K. E.
    Stangier, J.
    Nehmiz, G.
    Reilly, P.
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 : 482 - 483
  • [22] Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: A systematic review and meta-analysis
    Lip, Gregory Y. H.
    Edwards, Steven J.
    [J]. THROMBOSIS RESEARCH, 2006, 118 (03) : 321 - 333
  • [23] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
    Wolzt, M
    Wollbratt, M
    Svensson, M
    Wåhlander, K
    Grind, M
    Eriksson, UG
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (07) : 537 - 543
  • [24] Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects
    Michael Wolzt
    Maria Wollbratt
    Mia Svensson
    Karin Wåhlander
    Margaretha Grind
    Ulf G. Eriksson
    [J]. European Journal of Clinical Pharmacology, 2003, 59 : 537 - 543
  • [25] Utilization of warfarin in elderly patients with non-valvular atrial fibrillation.
    Youssef, H
    Pomerantz, SC
    Ciesielski, J
    Cavalieri, TA
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2004, 52 (04) : S112 - S112
  • [26] Effect and risk of novel oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation
    Kawada, Tomoyuki
    [J]. JOURNAL OF CARDIOLOGY, 2017, 70 (1-2) : 99 - 99
  • [27] DISCONTINUATION/INTERRUPTION OF WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
    Wang, J.
    Qiao, Y.
    Spivey, C. A.
    Liu, X.
    Phatak, H.
    Mardekian, J.
    Claflin, A. B.
    Kachroo, S.
    Abdulsatter, Y.
    Parker, R. B.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A763 - A763
  • [28] THROMBOEMBOLIC AND HAEMORRHAGIC EVENTS FOLLOWING DIRECT ORAL ANTICOAGULANTS (DOACS) DOSE ADJUSTMENT AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF)
    Sun, Wen
    Tam, Tsz Kin
    Yan, Bryan P.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 77 - 77
  • [29] Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice
    Rubboli, Andrea
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2019, 62 : E11 - E12
  • [30] Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation
    Meng, Shih-Wei
    Lin, Ting-Tse
    Liao, Min-Tsun
    Chen, Ho-Min
    Lai, Chao-Lun
    [J]. ACTA CARDIOLOGICA SINICA, 2019, 35 (01) : 42 - 54
12345